Survodutide Weekly Research Dosing Protocol
-
For research use only. Not medical advice.
Overview
Survodutide is a dual GLP-1/glucagon receptor agonist typically researched in the 0.6–6 mg weekly range, with gradual escalation over 10–12 weeks.
It produces strong appetite suppression and a pronounced metabolic effect due to its glucagon activity — much more aggressive than standard GLP-1 compounds.Slow titration is essential for GI tolerability.
Weekly Titration Schedule
Weeks 1–2: Intro Phase
Dose: 0.6 mg once weekly
Purpose: Allow subjects to adapt to GLP-1 + GC stimulation.
Notes: Even this low dose can feel strong for GLP-1-naive subjects.
Weeks 3–4: Light Phase
Dose: 1.2 mg once weekly
Appetite suppression increases significantly here.
Hold longer at 0.6 mg if nausea or fullness is excessive.
Weeks 5–6: Moderate Phase
Dose: 1.8 mg once weekly
Represents a comfortable mid-range dose for many subjects.
Escalate only if prior doses were well tolerated.
Weeks 7–8: Strong Phase
Dose: 2.4 mg once weekly
This dose often produces robust metabolic effects without overwhelming tolerability.
Many researchers remain here for multiple weeks before proceeding.
Weeks 9–10: High Phase
Dose: 3.6 mg once weekly
Strong GC-driven thermogenic activity emerges.
If subjects struggle at this point, step back to 2.4 mg until stable.
Weeks 11–12: Upper-Tier Phase
Dose: 4.8 mg once weekly
This was near the top end of phase 2 obesity trial dosing.
GI and appetite suppression effects intensify; titrate cautiously.
Week 13+ Maintenance
Two research-validated maintenance ranges:
Standard Maintenance
4.8 mg once weekly
Provides excellent efficacy with manageable tolerability.
Maximum Maintenance
6.0 mg once weekly
Represents the high end used in some modeling and extended research runs.
Move to 6.0 mg only after 4.8 mg is fully tolerated for several weeks.
Frequency & Timing
Once weekly at a consistent time.
Due to the glucagon component, many subjects experience delayed nausea (Day 2–3).
Avoid rushing escalations — Survodutide hits harder per mg than typical GLP-1s.
Cycle Length
Titration requires 10–12 weeks minimum.
Full research cycles typically last 20–48 weeks depending on goals and maintenance dose.
Common Research Notes
Survodutide is significantly stronger milligram-for-milligram than semaglutide or tirzepatide due to dual receptor activation.
GI load increases steeply with each escalation — slow progression improves tolerability.
When used in stacks (e.g., tirz + survo “Ghetto Reta”), researchers often cap survo at 0.6–1.5 mg because synergy multiplies the effect.
